Astel­las, Fi­bro­Gen hit pri­ma­ry end­point in PhI­II; vTv inks PDE4 in­hibitor deal with New­soara

→ Astel­las and Fi­bro­Gen are re­port­ing that their fourth late-stage study of rox­adu­s­tat hit the pri­ma­ry end­point for ane­mia in pa­tients with CKD.

→ North Car­oli­na’s vTv Ther­a­peu­tics watched its stock $VTVT soar over 40% on the news that its en­tered a li­cens­ing deal with New­soara Bio­phar­ma. The agree­ment al­lows New­soara to de­vel­op and com­mer­cial­ize vTv’s PDE4 in­hibitor pro­gram in Chi­na, Hong Kong, Macau, Tai­wan, and oth­er Pa­cif­ic Rim coun­tries.  New­soara will de­vel­op the clin­i­cal stage drug, called HPP737, for res­pi­ra­to­ry and oth­er in­flam­ma­to­ry dis­eases, ac­cord­ing to a com­pa­ny state­ment.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN